Meeting report: PDA virus and TSE safety forum

PDA Journal of Pharmaceutical Science and Technology

Volumn 67, Issue 2, 2013, Pages 81-97

  Willkommen, Hannelore ^a   Blümel, Johannes ^b   Brorson, Kurt ^c   Chen, Dayue ^d   Chen, Qi ^e   Gröner, Albrecht ^f   Kreil, Thomas R ^g   Robertson, James S ^h   Ruffing, Michel ⁱ   Ruiz, Sol ^j  

^a Regulatory Affairs and Biological Safety Consulting   (Germany)

^b PAUL EHRLICH INSTITUT   (Germany)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e GENENTECH INC   (United States)

^f CSL BEHRING GMBH   (Germany)

^g BAXTER BIOSCIENCE   (Austria)

^h NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

ⁱ Boehringer Ingelheim Pharma GmbH and KG   (Germany)

^j Spanish Medicines Agency ^*  (Spain)

more..

Author keywords

Biotechnology; Plasma derivatives; Regulatory affairs; Safety; TSE; Virus; Virus clearance

Indexed keywords

CONFERENCE PAPER; CREUTZFELDT JAKOB DISEASE; HUMAN; PARENTERAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRION DISEASE; QUALITY CONTROL; VIRAL CLEARANCE; VIRAL CONTAMINATION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS REPLICATION; ANIMAL; PRION; RISK; SAFETY; VIRUS;

PRION;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PRION DISEASES; PRIONS; RISK; SAFETY; VIRUSES;

EID: 84876860228     PISSN: 10797440     EISSN: 19482124     Source Type: Journal    
DOI: 10.5731/pdajpst.2013.00906     Document Type: Conference Paper

References (33)

1. ICH Q5A (R1): Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. CPMP/ICH/295/95. October 1997. http://www.ema.europa.eu.
2. Victoria, J. G.; Wang, C.; Jones, M. S.; Jaing, C.; McLoughlin, K.; Gardner, S.; Delwart, E. L. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033-6040.
3. EMA/CHMP/BWP/548524/2008: Guideline on epidemiological data on blood transmissible infection. 22 April 2010. http://www.ema.europa.eu.
4. Murphy, M.; Quesada, G. M.; Chen, D. Effectiveness of mouse minute virus inactivation by high temperature short time treatment technology: a statistical assessment. Biologicals 2011, 39 (6): 438 - 443.
5. Onions, D.; Kolman, J. Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38 (3), 377-380.
6. Sampath, R.; Blyn, L. B.; Ecker, D. J. Rapid molecular assays for microbial contaminant monitoring in the bioprocess industry. PDA J. Pharm. Sci. Technol. 2010, 64 (5), 458 - 464.
7. Ill, C. R.; Dehghani, H. Risk reduction in biotherapeutic products. Curr. Opin. Drug Discov. Devel. 2009, 12 (2), 296 -304.
8. Lawrence, B.; Bashiri, H.; Dehghani, H. Cross comparison of rapid mycoplasma detection platforms. Biologicals 2010, 38 (2), 218 -223.
9. Lamson, D.; Renwick, N.; Kapoor, V.; Liu, Z.; Palacios, G.; Ju, J.; Dean, A.; St. George, K.; Briese, T.; Lipkin, W. I. MassTag polymerasechain- reaction detection of respiratory pathogens, including a new rhinovirus genotype, that caused influenza-like illness in New York State during 2004 -2005. J. Infect. Dis. 2006, 194 (10), 1398 - 1402.
10. Palacios G.; Quan P.-L.; Jabado, O. J.; Conlan, S.; Hirschberg, D. L.; Liu, Y.; Zhai, J.; Renwick, N.; Hui, J.; Hegyi, H.; Grolla, A.; Strong, J. E.; Towner, J. S.; Geisbert, T. W.; Jarhling, P. B.; Büchen-Osmond, C. V.; Ellerbrok, H.; Sanchez- Seco, M. P.; Lussier, Y.; Formenty, P.; Nichol, S. T.; Feldmann, H.; Briese, T.; Lipkin, W. I. Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg. Infect. Dis. 2007, 13 (1), 73-81.
11. Briese, T.; Paweska, J. T.; McMullan, L. K.; Hutchison, S. K.; Street, C.; Palacios, G.; Khristova, M. L.; Weyer, J.; Swanepoel, R.; Egholm, M.; Nichol, S. T.; Lipkin, W. I. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog. 2009, 5 (5), e1000455.
12. Quan, P. L.; Wagner, T. A.; Briese, T.; Torgerson, T. R.; Hornig, M.; Tashmukhamedova, A.; Firth, C.; Palacios, G.; Baisre-de-Leon, A.; Paddock, C. D.; Hutchison, S. K.; Egholm, M.; Zaki, S. R.; Goldman, J. E.; Ochs, H. D.; Lipkin, W. I. Astrovirus encephalitis in boy with X-linked agammaglobulinemia. Emerg. Infect. Dis. 2010, 16 (6): 918 -925.
13. Farcet, M. R.; Kindermann, J.; Modrof, J.; Kreil, T. R. Inactivation of hepatitis A variants during heat treatment (pasteurization) of human serum albumin. Transfusion 2012, 52 (1), 181-187.
14. Miesegaes, G.; Bailey, M.; Willkommen, H.; Chen, Q.; Roush, D.; Blümel, J.; Brorson, K. Proceedings of the 2009 viral clearance symposium. Dev. Biol. 2011, 113, 3-104.
15. Dichtelmuller, H. O.; Biesert, L.; Fabrizzi, F.; Gajardo, R.; Groner, H.; Jorquera, J. I.; Kempf, C.; Kreil, T. R.; Pifat, W.; Osheroff, W.; Poelsler, G. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009, 49 (9), 1931-1943.
16. EMEA/CHMP/BWP/398498/2005: Guideline on virus safety evaluation of biotechnological investigational medicinal products. 1 February 2009. http://www.ema.europa.eu.
17. OIE-World Organization of Animal Health: Bovine Spongiform Encephalopathy Status of Members according to Resolution No. 17, May 2011, http://www.oie.int/animal-health-in-the-world/official- disease-status/bse/list- of-bse-risk-status/.
18. National Blood Service: Transfusion Medicine Epidemiologial Review (TMER). http://www.cjd. ed.ac.uk/TMER/TMER.htm.
19. Peden, A.; McCardle, L.; Head, M. W.; Love, S.; Ward, H. J. T.; Cousens, S. N.; Keeling, D. M.; Millar, C. M.; Hill, F. G. H.; Ironside, J. W. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010, 16 (2), 296 -304.
20. Puopolo, M.; Ladogana, A.; Vetrugno, V.; Pocchiari, M. Transmission of sporadic Creutzfeldt- Jakob disease by blood transfusion: risk factor or possible biases. Transfusion 2011, 51 (7), 1556 - 1566.
21. European Commission: Note for guidance on minimizing the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev. 3). OJ C73, 5.3.2011, pp 1-18.
22. OIE: Terrestrial Animal Health Code, Chapter 11.5.: bovine spongiform encephalopathy. http://www.oie.int/index.php?id-169&L-0&htmfile- chapitre-1.11.5.htm.
23. EMA/CHMP/BWP/303353/2010: CHMP position statement on Creutzfeldt-Jakob disease and plasma- derived and urine-derived medicinal products. 23 June 2011. http://www.ema.europa.eu.
24. Hilton, D. A.; Ghani, A. C.; Conyers, L.; Edwards, P.; McCardle, L.; Ritchie, D.; Penney, M.; Hegazy, D.; Ironside, J. W. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J. Pathol. 2004, 203 (3), 733-739.
25. de Marco, M. F.; Linehan, J.; Gill, O. N.; Clewley, J. P.; Brandner, S. Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. J. Pathol. 2010, 222 (4), 380 -387.
26. Gregori, L.; Kovacs, G. G.; Alexeeva, I.; Budka, H.; Rohwer, R. G. Excretion of transmissible spongiform encephalopathy infectivity in urine. Emerg. Infect. Dis. 2008, 14 (9), 1406 -1412.
27. Edgeworth, J. A.; Farmer, M.; Sicilia, A.; Tavares, P.; Beck, J.; Campbell, T.; Lowe, J.; Mead, S.; Rudge, P.; Collinge, J.; Jackson, G. S. Detec- tion of prion infection in variant Creutzfeldt-Jakob disease: a blood based assay. Lancet 2011, 377 (9764), 487-493.
28. Wilham, J. M.; Orrú, C. D.; Bessen, R. A.; Atarashi, R.; Sano, K.; Race, B.; Meade-White, K. D.; Taubner, L. M.; Timmes, A.; Caughey, B. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. 2010, 6 (12), e1001217, doi: 10.1371/journal.ppat. 1001217.
29. Pritzkow, S.; Wagenführ, K.; Daus, M. L.; Boerner, S.; Lemmer, K.; Thomzig, A.; Mielke, M.; Beekes, M. Quantitative detection and biological propagation of scrapie seeding activity in vitro facilitate use of prions as model pathogens for disinfection. PLoS One 2011, 6 (5), e20384, doi: 10.1371/journal.pone.0020384.
30. Thyer, J.; Unal, A.; Hartel, G.; Middleton, D.; Bingham, J.; Braun, M.; Uren, E.; Maher, D. Investigation of prion removal/inactivation from chromatographic gel. Vox Sang. 2006, 91 (4), 301-308.
31. CPMP/BWP/5136/03: Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regards to vCJD. 21 October 2004. http://www.ema.europa.eu.
32. Yunoki, M.; Tanaka, H.; Urayama, T.; Hattori, S.; Ohtani, M.; Ohkubo, Y.; Kawabata, Y.; Miyatake, Y.; Nanjo, A.; Iwao, E.; Morita, M.; Wilson, E.; MacLean, C.; Ikuta, K. Prion removal by nanofiltration under different experimental conditions. Biologicals 2008, 36 (1), 27-36.
33. Safar, J. G.; Geschwind, M. D.; Deering, C.; Didorenko, S.; Sattavat, M.; Sanchez, H.; Serban, A.; Vey, M.; Baron, H.; Giles, K.; Miller, B. L.; DeArmond, S. J. Diagnosis of human prion disease. Proc. Natl. Acad. Sci. 2005, 102 (9), 3501-3506.